Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023

Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023

Urticaria is an itchy rash that appears on the skin. It may appear on one part of the body or be spread across large areas. Chronic urticaria is a mast cell-mediated condition characterized by the recurrent occurrence of urticaria and/or angioedema.

The welts that come with hives are caused by the release of immune system chemicals, such as histamine, into the bloodstream. The skin reaction may be triggered by heat or cold, sunlight, vibration, pressure on the skin, medical conditions, such as thyroid disease, infection, allergy, and cancer.

Symptoms of chronic hives includes batches of welts (wheals) that can arise anywhere on the body, welts that might be red, purple, or skin colored. Welts that vary in size, change shape, and appear and fade repeatedly, Itchiness (pruritus), which can be intense, painful swelling (angioedema) around the eyes, cheeks, or lips.

Doctors most often diagnose chronic urticaria by examining the rash. The tests include complete blood count, erythrocyte sedimentation rate and C reactive protein are important investigations for diagnosis of infections in urticaria.

The most common investigative treatments include antihistamines. These drugs ease itching, swelling and other allergy symptoms. Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), taken regularly, are the first-line pharmacological treatment. Omalizumab given as a subcutaneous injection is a second-line adjunct therapy for CSU that is unresponsive to H1-antihistamines.

Symptoms can be eased through lifestyle changes and home remedies like comfortably cool shower or bath, wear loose, smooth-textured cotton clothing and protect your skin from the sun.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chronic Urticaria or Hives treatment such as CT-P39, Dupilumab, LOU064, TEV-45779, Tezepelumab and others. Key players involved in the development of therapies to treat Chronic Urticaria or Hives are Amgen, Celltrion, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA and others. Eight drugs are under late-stage Phase III clinical trials and Nine drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0 and Preclinical stages of development.

In December 2022, Allakos announced the proof-of-concept results of Lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.

Report Highlights

Global Insight Service's, Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023 report provides an overview of the Chronic Urticaria or Hives pipeline drugs. This report covers detailed insights on Chronic Urticaria or Hives drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chronic Urticaria or Hives pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.